Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Amphastar Pharmaceuticals (DE:29A)
FRANKFURT:29A
RESEARCH TOOLSreports
Holding DE:29A?
Track your performance easily
29A Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€34.10 - €58.50
Previous Close€41.63
Volume0.00
Average Volume (3M)380.00
Market Cap
€2.06B
Enterprise Value€2.43B
Total Cash (Recent Filing)$217.78M
Total Debt (Recent Filing)$620.58M
Price to Earnings (P/E)―
Beta0.09
Next Earnings
Nov 04, 2024EPS Estimate
€0.92Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding48,675,822
10 Day Avg. Volume0
30 Day Avg. Volume380
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)2.84
Price to Sales (P/S)3.16
Price to Cash Flow (P/CF)8.20
P/FCF Ratio8.90
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.40
Enterprise Value/Gross Profit6.91
Enterprise Value/Ebitda8.10
Forecast
1Y Price Target
€54.60Price Target Upside31.16% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
Amphastar Pharmaceuticals News
PremiumCompany Announcements
Amphastar Pharmaceuticals Advances Governance and Shareholder Value
Bulls Say, Bears Say
Bulls Say
Financial StrengthThe company appears well positioned for more tuck-in BD; AMPH has over $200MM of cash on the balance sheet and a net leverage ratio below 2x.
Market PositionBAQSIMI is currently the market-share-leading product in the branded glucagon market and the only non-injectable product.
Product PerformanceKey branded products like BAQSIMI and Primatene Mist OTC are continuing to perform well, largely driven by volume growth.
Bears Say
EarningsMixed pipeline commentary and competition in generic glucagon lead to trim FY24E (-3%; now closer to consensus).
Market ConstraintsAMP-002 is expected to be capacity constrained for a protracted period in this two-player market.
Product ProspectsGx naloxone commercial prospects were downplayed while Gx Albuterol could see slower initial ramp.
---
29A FAQ
What was Amphastar Pharmaceuticals’s price range in the past 12 months?
Amphastar Pharmaceuticals lowest stock price was €34.10 and its highest was €58.50 in the past 12 months.
What is Amphastar Pharmaceuticals’s market cap?
Currently, no data Available
When is Amphastar Pharmaceuticals’s upcoming earnings report date?
Amphastar Pharmaceuticals’s upcoming earnings report date is Nov 04, 2024 which is in 24 days.
How were Amphastar Pharmaceuticals’s earnings last quarter?
Amphastar Pharmaceuticals released its earnings results on Aug 07, 2024. The company reported €0.856 earnings per share for the quarter, beating the consensus estimate of €0.703 by €0.153.
Is Amphastar Pharmaceuticals overvalued?
According to Wall Street analysts Amphastar Pharmaceuticals’s price is currently Undervalued.
Does Amphastar Pharmaceuticals pay dividends?
Amphastar Pharmaceuticals does not currently pay dividends.
What is Amphastar Pharmaceuticals’s EPS estimate?
Amphastar Pharmaceuticals’s EPS estimate is €0.92.
How many shares outstanding does Amphastar Pharmaceuticals have?
Amphastar Pharmaceuticals has 48,675,823 shares outstanding.
What happened to Amphastar Pharmaceuticals’s price movement after its last earnings report?
Amphastar Pharmaceuticals reported an EPS of €0.856 in its last earnings report, beating expectations of €0.703. Following the earnings report the stock price went up 4.341%.
Which hedge fund is a major shareholder of Amphastar Pharmaceuticals?
Among the largest hedge funds holding Amphastar Pharmaceuticals’s share is Hussman Strategic Advisors Inc. It holds Amphastar Pharmaceuticals’s shares valued at 3M.
---
Amphastar Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€54.60 (31.16% Upside)
€54.60 (31.16% Upside)
Blogger Sentiment
Bullish
DE:29A Sentiment 88%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $1.2M over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
-2.58%
12-Months-Change
Fundamentals
Return on Equity
25.57%
Trailing 12-Months
Asset Growth
8.22%
Trailing 12-Months
Company Description
Amphastar Pharmaceuticals
Amphastar Pharmaceuticals, Inc. engages in the development, manufacture, market, and sale of technically challenging and proprietary injectable, inhalation, and intranasal products. It operates through Finished Pharmaceutical Products, and Active Pharmaceutical Ingredients Products segments. The Finished Pharmaceutical Products segment manufactures, markets and distributes enoxaparin, cortrosyn, amphadase, naloxone, lidocaine jelly, as well as various other critical and non-critical care drugs. The Active Pharmaceutical Ingredients Products segment manufactures and distributes recombinant human insulin and porcine insulin. The company was founded by Zi-Ping Luo and Yong Feng Zhang on February 29, 1996 and is headquartered in Rancho Cucamonga, CA.
---
29A Company Deck
---
29A Earnings Call
Q2 2024
0:00 / 0:00
---
29A Stock 12 Month Forecast
Average Price Target
€54.60
▲(31.16% Upside)
Technical Analysis
Amphastar Pharmaceuticals
―
ACADIA Pharmaceuticals
―
Catalyst Pharma
―
Heron Therapeutics
―
Amarin
―
Best Analysts Covering 29A
1 Year
1 Year Success Rate
15/17 ratings generated profit
1 Year Average Return
+27.25%
assigned a buy rating 2 months ago
Copying Tim Chiang's trades and holding each position for 1 Year would result in 88.24% of your transactions generating a profit, with an average return of +27.25% per trade.
---